These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 9427051)

  • 1. Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children.
    Pasetti M; Eriksson P; Ferrero F; Manghi M
    Infection; 1997; 25(6):339-45. PubMed ID: 9427051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.
    Torbicka E; Lagergård T; Trollfors B
    Infection; 1995; 23(4):212-5. PubMed ID: 8522378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
    Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
    Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two primary doses of diphtheria-tetanus-acellular pertussis vaccine induce immunological responses to Bordetella pertussis as strong as those induced by three primary doses.
    Tomoda T; Ogura H; Kurashige T
    Vaccine; 1997 Dec; 15(17-18):1955-8. PubMed ID: 9413107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children.
    Pichichero ME; Badgett JT; Rodgers GC; McLinn S; Trevino-Scatterday B; Nelson JD
    Pediatr Infect Dis J; 1987 Apr; 6(4):352-63. PubMed ID: 3495775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
    Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F
    Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
    Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
    Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric diphtheria and tetanus toxoids-adsorbed vaccine: immune response to the first booster following the diphtheria and tetanus toxoids vaccine primary series.
    Pichichero ME; Barkin RM; Samuelson JS
    Pediatr Infect Dis; 1986; 5(4):428-30. PubMed ID: 3487779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
    Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
    Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.